Fewer than 1 in 1,000 US adolescents receive gender-affirming medications, researchers find
- Fewer than 1 in 1,000 U.S. Adolescents with commercial insurance received gender-affirming medications during a recent five-year period, according to the study released Monday.
- The findings, published in JAMA Pediatrics, indicate that fewer than 0.1% of all youth in the database received these medications.
- Only 926 adolescents with a gender-related diagnosis received puberty blockers from 2018 through 2022, while 1,927 received hormones.
- No patients under age 12 were prescribed hormones, indicating that doctors are appropriately cautious about when to start such treatments, said Hughes.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left16Leaning Right4Center41Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 26%
C 67%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
